LUND, Sweden, May 17, 2023 /PRNewswire/ -- Immunovia will
publish its first quarter 2023 results on May 23, 2023 at 8:30 am
CET. Analysts, investors and media are invited to a webcast
teleconference on the same day at 15:00
CET. The report together with the presentation slides will
be available at www.immunovia.com
Jeff Borcherding, CEO and
President, and Karin Almqvist Liwendahl, CFO, will present on
Immunovia's development. The presentation will be held in English
and be followed by a Q&A session. You are welcome to join via
webcast or phone, see details below.
Telephone numbers and webcast
Call any of the numbers below to participate via telephone.
Please dial in a few minutes before the presentation starts.
Sweden: +46 (0)8 5051 0031
United Kingdom: +44 (0) 207 107 06
13
United States: +1 (1) 631 570 56
13
Link to the
webcast: https://access.creomediamanager.com/registration/058aa458-36d2-4352-9dbf-1894dc75828d?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F058aa458-36d2-4352-9dbf-1894dc75828d
To ask questions, it is necessary to dial in. A recording of the
presentation will be available on Immunovia's website.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
About Immunovia
Immunovia is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer
groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated, addressable market size of 1.8 million individuals per
year who could benefit from our test.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
|
https://mb.cision.com/Main/13121/3771245/2066728.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/invitation-to-immunovias-q1-presentation-301827069.html